SCHEDULE: Mirabella Financial Services LLP Discloses Zero Beneficial Ownership

Mirabella Financial Services LLP has filed a Schedule 13G, reporting zero shares beneficially owned in Maxcyte, Inc. as of March 31, 2026, due to no longer acting as Investment Manager for Blue Riband Fund LP.

Summary

• Mirabella Financial Services LLP has filed an amendment to its Schedule 13G filing concerning Maxcyte, Inc.
• The filing indicates that as of March 31, 2026, Mirabella Financial Services LLP beneficially owns 0 shares of Maxcyte, Inc. common stock.
• This represents 0% of the class of securities.
• The reason for this change is that Mirabella Financial Services LLP no longer acts as the Investment Manager for Blue Riband Fund LP since January 5, 2026.
• Consequently, Mirabella Financial Services LLP no longer has discretion over the voting and dispositive power for these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative, reporting a change in investment management status rather than a change in the company's operational or financial performance.

Negatives

• Mirabella Financial Services LLP no longer holds any beneficial ownership in Maxcyte, Inc., indicating a complete divestment or cessation of management responsibility for the shares previously held by Blue Riband Fund LP.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding future share ownership or investment strategies.

Management Comments

• "This notification is to advise that since 5th January 2026, Mirabella Financial Services LLP no longer acts as the Investment Manager for Blue Riband Fund LP. Therefore, Mirabella no longer has discretion for the exercise of voting and dispositive power over the shares."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors and indicate changes in significant beneficial ownership. A filing reporting zero ownership suggests a complete cessation of investment management or a transfer of control for the securities in question.

Stakeholder Impact

• Shareholders of Maxcyte, Inc. may note the change in reporting entity, though the actual number of shares held by the fund remains unchanged if the fund itself still holds the shares under new management.
• Blue Riband Fund LP stakeholders will be impacted by the change in investment manager, potentially leading to a shift in investment strategy or oversight for their holdings in Maxcyte, Inc.

Key Dates

Keywords

Maxcyte Inc, Schedule 13G, Beneficial Ownership, SEC Filing, Investment Manager, Mirabella Financial Services LLP, Securities Exchange Act